The price-to-earnings ratio for Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is above average at 18.55x. The 36-month beta value for CPRX is also noteworthy at 0.70. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CPRX is 111.11M, and at present, short sellers hold a 7.01% of that float. The average trading volume of CPRX on May 02, 2025 was 1.25M shares.
CPRX) stock’s latest price update
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has experienced a decline in its stock price by -0.08 compared to its previous closing price of 24.29. However, the company has seen a gain of 4.66% in its stock price over the last five trading days. zacks.com reported 2025-04-30 that Catalyst (CPRX) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CPRX’s Market Performance
Catalyst Pharmaceuticals Inc (CPRX) has seen a 4.66% rise in stock performance for the week, with a 1.46% gain in the past month and a 4.66% surge in the past quarter. The volatility ratio for the week is 3.34%, and the volatility levels for the past 30 days are at 4.83% for CPRX. The simple moving average for the past 20 days is 5.93% for CPRX’s stock, with a 13.92% simple moving average for the past 200 days.
Analysts’ Opinion of CPRX
Many brokerage firms have already submitted their reports for CPRX stocks, with Robert W. Baird repeating the rating for CPRX by listing it as a “Outperform.” The predicted price for CPRX in the upcoming period, according to Robert W. Baird is $28 based on the research report published on February 04, 2025 of the current year 2025.
Stephens, on the other hand, stated in their research note that they expect to see CPRX reach a price target of $35. The rating they have provided for CPRX stocks is “Overweight” according to the report published on November 18th, 2024.
Citigroup gave a rating of “Buy” to CPRX, setting the target price at $27 in the report published on March 14th of the previous year.
CPRX Trading at 6.79% from the 50-Day Moving Average
After a stumble in the market that brought CPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.22% of loss for the given period.
Volatility was left at 4.83%, however, over the last 30 days, the volatility rate increased by 3.34%, as shares sank -0.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.72% upper at present.
During the last 5 trading sessions, CPRX rose by +4.66%, which changed the moving average for the period of 200-days by +44.90% in comparison to the 20-day moving average, which settled at $22.91. In addition, Catalyst Pharmaceuticals Inc saw 16.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CPRX starting from INGENITO GARY, who sale 180,096 shares at the price of $21.67 back on Mar 06 ’25. After this action, INGENITO GARY now owns 68,873 shares of Catalyst Pharmaceuticals Inc, valued at $3,902,680 using the latest closing price.
INGENITO GARY, the Chief Med. & Reg. Officer of Catalyst Pharmaceuticals Inc, sale 44,904 shares at $22.09 during a trade that took place back on Mar 05 ’25, which means that INGENITO GARY is holding 68,873 shares at $991,929 based on the most recent closing price.
Stock Fundamentals for CPRX
Current profitability levels for the company are sitting at:
- 0.4 for the present operating margin
- 0.84 for the gross margin
The net margin for Catalyst Pharmaceuticals Inc stands at 0.33. The total capital return value is set at 0.27. Equity return is now at value 29.38, with 24.71 for asset returns.
Based on Catalyst Pharmaceuticals Inc (CPRX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 75.22.
Currently, EBITDA for the company is 232.9 million with net debt to EBITDA at -2.4. When we switch over and look at the enterprise to sales, we see a ratio of 4.97. The receivables turnover for the company is 7.51for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.17.
Conclusion
In summary, Catalyst Pharmaceuticals Inc (CPRX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
